Arovella Therapeutics Limited (AU:ALA)

ASX:ALA

ALA

Arovella Therapeutics Limited

RESEARCH TOOLSreports

Want to see AU:ALA full AI Analyst Report?

Arovella Therapeutics Limited (ALA) Price & Analysis

18 Followers

ALA Stock Chart & Stats

AU$0.08

AU$0.00(0.00%)

At close: Jan 07 4:00 PM EST

AU$0.08

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.07 - AU$0.13

Previous CloseN/A

Volume194.12K

Average Volume (3M)1.58M

Market Cap

AU$91.87M

Enterprise ValueAU$72.50M

Total Cash (Recent Filing)AU$19.37M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding1,208,783,700

10 Day Avg. Volume1,549,358

30 Day Avg. Volume1,578,675

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)5.47

Price to Sales (P/S)806.87

P/FCF Ratio-14.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low Leverage / No DebtZero reported debt meaningfully reduces financial risk and interest burden for an early‑stage biotech. This structural advantage gives management flexibility to allocate equity capital to R&D and partnerships, extending strategic optionality and lowering near‑term refinancing pressure over the next several months.

Materially Strengthened Equity BaseA significantly larger equity base provides a capital buffer to support preclinical and early clinical programs without immediate insolvency risk. This strengthens the company’s balance sheet resilience, improves runway visibility, and enhances credibility for partnership or licensing discussions over the medium term.

Focused Cell‑therapy R&D PlatformA clear strategic focus on engineered immune‑cell therapies (iNKT and CAR) creates a durable product development roadmap and technical differentiation. The platform aligns with structural growth in oncology cell therapies, supporting long‑term partnership and licensing potential if clinical progress continues.

Bears Say

Consistent Negative Cash GenerationPersistent negative operating and free cash flow means the company is not self‑funding and must rely on external capital or partnerships. Over 2‑6 months this elevates dilution and financing risk, constraining the pace of parallel clinical programs and strategic flexibility absent new funding.

Small, Volatile And Declining RevenueThe absence of predictable, material revenue indicates no commercialized product and makes cashflow planning uncertain. A sharp revenue decline increases reliance on capital markets and milestone deals, raising execution risk and making multi‑program development harder to sustain without fresh funding.

Sustained Operating Losses And Negative MarginsContinued large operating losses generate negative returns on equity and can erode the strengthened capital base if sustained. Without clinical success or meaningful non‑dilutive financing, persistent losses will limit strategic choices, increase funding dependency, and lengthen the path to commercial breakeven.

Arovella Therapeutics Limited News

Arovella Therapeutics Options Lapse Clarifies Capital Structure

An announcement from Arovella Therapeutics Limited ( ($AU:ALA) ) is now available. Arovella Therapeutics has reported the cessation...

2d ago

Arovella Therapeutics Reports Director Andrew Nash’s Departure With No Security Interests

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics Limited has notified the ASX that...

3d ago

Arovella Highlights Solid-Tumour CAR-iNKT Advances at Global Cell Therapy Meeting

An update from Arovella Therapeutics Limited ( ($AU:ALA) ) is now available. Arovella Therapeutics showcased new pre-clinical data...

3d ago

Arovella names acting CEO as it heads into key Phase I trial

Arovella Therapeutics Limited ( ($AU:ALA) ) has issued an update. Arovella Therapeutics has appointed Chief Operating Officer Dr...

3d ago

Arovella Overhauls Board as CEO Resigns, Launches Strategic Review

Arovella Therapeutics Limited ( ($AU:ALA) ) just unveiled an update. Arovella Therapeutics has undergone a major board overhaul...

6d ago

Arovella Appoints New Director With No Current Shareholdings

Arovella Therapeutics Limited ( ($AU:ALA) ) has issued an announcement. Arovella Therapeutics Limited has announced the appointment of...

9d ago

Arovella boosts board with four senior biotech and finance appointments

Arovella Therapeutics Limited ( ($AU:ALA) ) just unveiled an announcement. Arovella Therapeutics has strengthened its board as part...

12d ago

Arovella shareholder withdraws invalid requisition, easing governance overhang

Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an announcement. Arovella Therapeutics has announced that the shareholder who...

17d ago

Arovella Rejects Shareholder Board Requisition as Invalid

Arovella Therapeutics Limited ( ($AU:ALA) ) has issued an announcement. Arovella Therapeutics has rejected a shareholder’s attempt to...

18d ago

Arovella Showcases CLDN18.2 CAR-iNKT Solid Tumour Data at AACR

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics presented new pre-clinical data on its...

20d ago

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?

Arovella Therapeutics Limited lowest share price was AU$0.07 and its highest was AU$0.13 in the past 12 months.

What is Arovella Therapeutics Limited’s market cap?

Arovella Therapeutics Limited’s market cap is AU$91.87M.

When is Arovella Therapeutics Limited’s upcoming earnings report date?

Arovella Therapeutics Limited’s upcoming earnings report date is Sep 02, 2026 which is in 115 days.

How were Arovella Therapeutics Limited’s earnings last quarter?

Arovella Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.

Is Arovella Therapeutics Limited overvalued?

According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arovella Therapeutics Limited pay dividends?

Arovella Therapeutics Limited does not currently pay dividends.

What is Arovella Therapeutics Limited’s EPS estimate?

Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arovella Therapeutics Limited have?

Arovella Therapeutics Limited has 1,208,783,700 shares outstanding.

What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?

Arovella Therapeutics Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.706%.

Which hedge fund is a major shareholder of Arovella Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:ALA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arovella Therapeutics Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-40.65%

Trailing 12-Months

Asset Growth

60.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arovella Therapeutics Limited

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.